Amydis Diagnostics Inc.
Small molecule fluorescent retinal contrast agents for non-invasive detection and quantification of TDP43 pathology in the eye
- Sector
- Medtech
- Headquarters
- San Diego, CA
- Total capital
- $10.9M
- Federal grants
- $10.9M
- 14 awards · 2015–2025
- Rank in peer group#2 of 28
- Private capital raised
- None on recordNo Form D filings on SEC EDGAR. Some raises are not filed.
- Federal contracts
- None on recordNo federal contract awards found.
- Granted patents
- 0
- 1 pending
Capital timeline
Latest events
- Federal grantHealth and Human S · Phase II · Development of a topical tracer to detect TDP43 in ALS, LATE and FTD retinas for AI-powered disease insights$1.4M
- Federal grantHealth and Human S · Phase II · Differential diagnosis of Parkinson's and multiple system atrophy in non-human primate models using a novel a-synuclein retinal contrast agent and AI-assisted analytics$900K
- Federal grantHealth and Human S · Phase I · Development of a novel fluorescent tracer for detection of retinal TDP43 in ALS and FTD$459K
- Federal grantHealth and Human S · Phase I · Development of a novel fluorescent tracer for detection of retinal TDP43 in ALS and FTD$459K
- Federal grantHealth and Human S · Phase II · Differential diagnosis of Parkinson's and multiple system atrophy in non-human primate models using a novel a-synuclein retinal contrast agent and AI-assisted analytics$2.1M
- Federal grantHealth and Human S · Phase I · Development of Novel Tau Retinal Tracers for Alzheimer's Disease and other Tauopathies$492K
- Federal grantHealth and Human S · Phase II · Development of a novel ophthalmic probe for cerebral amyloid angiopathy$1M
Show 7 earlier federal awards
- Federal grantHealth and Human S · Phase II · Development of a novel ophthalmic probe for cerebral amyloid angiopathy$490K
- Federal grantHealth and Human S · Phase I · Development of Novel Prion Disease Diagnostic$408K
- Federal grantHealth and Human S · Phase I · Development of Novel Prion Disease Diagnostic$408K
- Federal grantHealth and Human S · Phase I · Development of a Novel Diagnostic Probe for Cerebral Amyloid Angiopathy$535K
- Federal grantHealth and Human S · Phase II · Development of an ophthalmic diagnostic probe for neurodegenerativedisorders$211K
- Federal grantHealth and Human S · Phase II · Development of an ophthalmic diagnostic probe for neurodegenerativedisorders$1.6M
- Federal grantHealth and Human S · Phase I · Development of an ophthalmic diagnostic probe for neurodegenerative disorders$384K
Node area is scaled to amount. Form D reports securities sold, which can differ from an announced round; filings are numbered in the order they were made.
Standing among 28 peers
Line = medianMedtech · Molecule
- Federal grants#2 · top 7%
- Linked publications#5 · top 18%
Cumulative measures favor older companies. Rankings describe position today, not outcome. Below the median, ranks show as a band rather than a number.
Founders and team
No founders are linked to this company yet.
Founders appear once a person is matched to the company through its own patents, grants or filings. We never infer people from social profiles.
Checked: USPTO inventors; federal award principal investigators; SEC Form D related persons · Oct 23, 2026
Claim this profile to add your teamWhat it has protected
USPTO · 0 granted of 1- PendingIn Vitro Compositions Comprising Human Sample And Amyloid Targeting AgentUSPTOApplication PCTUS2015049825
Recent research by its founders
- Safety, Tolerability and Efficacy of Tazbententol in Healthy Volunteers and ALS Participants: An Adaptive Phase 1/2a Trial20260 cites
- SPG601-associated modulation of resting-state EEG and improvement in executive function in a fragile X syndrome randomized controlled crossover study20260 cites
- SPG302 protects retinal ganglion cells and preserves visual function by preserving synaptic activity in a mouse model of glaucoma20252 cites
Related companies, and why
- AEROCYTEK, INC.Similar federal contract value in Medtech · null in contracts
- JPTECHNOLOGIES, INC.Similar federal contract value in Medtech · null in contracts
- NEFER KA LLCSimilar federal contract value in Medtech · null in contracts
- JINGA-HI, INC.Similar federal contract value in Medtech · null in contracts
- BIOANALYTICAL SYSTEMS, INC. (BASI)Similar federal contract value in Medtech · null in contracts
- BIOPOWERTECHSimilar federal contract value in Medtech · null in contracts
Regulatory activity · Medtech
- New Animal Drugs; Approval of New Animal Drug Applications; Withdrawal of Approval of New Animal Drug Application; Change of SponsorFood and Drug Administration
- Medical Devices; General and Plastic Surgery Devices; Classification of the Skin Patch for Treatment of HyperhidrosisFood and Drug Administration
- Medical Devices; Anesthesiology Devices; Classification of the Monitor for Opioid Induced Impairment of OxygenationFood and Drug Administration
- Medical Devices; Orthopedic Devices; Classification of the Medial Knee Implanted Shock AbsorberFood and Drug Administration
- Medical Devices; Neurological Devices; Classification of the External Lower Extremity Nerve Stimulator for Restless Legs SyndromeFood and Drug Administration
- Medical Devices; General Hospital and Personal Use Devices; Classification of the Infant Supine Sleep SystemFood and Drug Administration
Rules are matched to sector, not to company. Recent activity in a sector is context rather than a signal about this business — until rules are matched to what a company actually builds, the section is shown as context and nothing more.
Sources
Federal grants from SBIR/STTR, NIH, NSF and DoD records. Federal contracts from USAspending.gov. Private capital from SEC Form D. Patents from USPTO. Publications from OpenAlex. Regulatory activity from the Federal Register. Press matched on company name.
How to read this page
Figures show associations in public records, not causes or predictions. Nothing here is investment advice. An em-dash means no record was found under this company's name, not that none exists.
Data freshness
SEC Form D filings through . SBIR and STTR awards through .